EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access · CC BY 4.0

Final outcome analysis from the phase II TUXEDO-1 trial of trastuzumab-deruxtecan in HER2-positive breast cancer patients with active brain metastases

Rupert Bartsch iD, Anna Sophie Berghoff, Julia Furtner, Maximilian Marhold, Elisabeth Sophie Bergen, Sophie Roider-Schur, Maximilian Johannes Mair, Angelika Martina Starzer, Heidrun Forstner, Beate Rottenmanner, Marie-Bernadette Aretin, Karin Dieckmann und 14 weitere

Neuro-Oncology · 05.12.2024 · 26 (12) · 2305-2315

DOI: 10.1093/neuonc/noae123 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Neuro-Oncology, online erschienen am 04.07.2024. Verfasst von Rupert Bartsch und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine I, Division of Oncology, Medical University of Vienna, Vienna, Austria. Hauptthemen laut MEDLINE: Brain Neoplasms, Breast Neoplasms, Immunoconjugates, Erb-b2 Receptor Tyrosine Kinases. Die Arbeit wurde bisher 54-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Daiichi-Sankyo.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Brain metastases (BM) are a devastating complication of HER2-positive metastatic breast cancer (BC) and treatment strategies providing optimized local and systemic disease control are urgently required. The antibody-drug conjugate trastuzumab deruxtecan (T-DXd) improved progression-free survival (PFS) and overall survival (OS) over trastuzumab emtansine but data regarding intracranial activity is limited. In the primary outcome analysis of TUXEDO-1, a high intracranial response rate (RR) was reported with T-DXd. Here, we report the final PFS and OS results. Patients and Methods TUXEDO-1 accrued adult patients with HER2-positive BC and active BM (newly diagnosed or progressing) without indication for immediate local therapy. The primary endpoint was intracranial RR; secondary endpoints included PFS, OS, safety, quality-of-life (QoL), and neurocognitive function. PFS and OS were estimated with the Kaplan-Meier method and analyzed in the per-protocol population.

Results

At 26.5 months median follow-up, median PFS was 21 months (95% CI: 13.3–n.r.) and median OS was not reached (95% CI: 22.2–n.r.). With longer follow-ups, no new safety signals were observed. The most common grade 3 adverse event was fatigue (20%). Grade 2 interstitial lung disease and a grade 3 symptomatic drop of left-ventricular ejection fraction were observed in one patient each. QoL was maintained over the treatment period.

Conclusions

T-DXd yielded prolonged intra- and extracranial disease control in patients with active HER2-positive BC BM in line with results from the pivotal trials. These results support the concept of antibody-drug-conjugates as systemic therapy for active BM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Brain NeoplasmsBreast NeoplasmsImmunoconjugatesErb-b2 Receptor Tyrosine KinasesTrastuzumabAdultAgedFemaleHumansMiddle AgedAntineoplastic Combined Chemotherapy ProtocolsCamptothecinFollow-Up StudiesPrognosisQuality of LifeSurvival Rate

Stichwörter der Autor:innen

HER2-positivebrain metastasesbreast cancertrastuzumab deruxtecan

Substanzen

CamptothecinImmunoconjugatesErb-b2 Receptor Tyrosine KinasesTrastuzumabERBB2 protein, humantrastuzumab deruxtecan

Autor:innen und Institutionen

  • Department of Medicine I, Division of Oncology, Medical University of Vienna, Vienna, Austria.
  • Research Center for Medical Image Analysis and Artificial Intelligence (MIAAI), Faculty of Medicine and Dentistry, Danube Private University, Krems, Austria.
  • Department of Radiology, Medical University of Vienna, Vienna, Austria.
  • Department of Oncology, St. Joseph's Hospital, Vienna, Austria.
  • Hospital Pharmacy, Vienna General Hospital and Medical University of Vienna, Vienna, Austria.
  • Department of Radio-Oncology, Medical University of Vienna, Vienna, Austria.

ORCID-Profile: Rupert Bartsch, Georg Widhalm, Matthias Preusser

Förderung

  • Daiichi-Sankyo

Zitieren

APA

Bartsch, R., Berghoff, A. S., Furtner, J., Marhold, M., Bergen, E. S., Roider-Schur, S., Mair, M. J., Starzer, A. M., Forstner, H., Rottenmanner, B., Aretin, M. B., Dieckmann, K., Bago-Horvath, Z., Haslacher, H., Widhalm, G., Ilhan-Mutlu, A., Minichsdorfer, C., Fuereder, T., Szekeres, T., …, & Preusser, M. (2024). Final outcome analysis from the phase II TUXEDO-1 trial of trastuzumab-deruxtecan in HER2-positive breast cancer patients with active brain metastases. Neuro-Oncology, 26(12), 2305-2315. https://doi.org/10.1093/neuonc/noae123

Vancouver

Bartsch R, Berghoff AS, Furtner J, Marhold M, Bergen ES, Roider-Schur S, et al. Final outcome analysis from the phase II TUXEDO-1 trial of trastuzumab-deruxtecan in HER2-positive breast cancer patients with active brain metastases. Neuro-Oncology. 2024;26(12):2305-2315. doi:10.1093/neuonc/noae123

BibTeX
@article{Bartsch2024,
  author = {Bartsch, Rupert and Berghoff, Anna Sophie and Furtner, Julia and Marhold, Maximilian and Bergen, Elisabeth Sophie and Roider-Schur, Sophie and Mair, Maximilian Johannes and Starzer, Angelika Martina and Forstner, Heidrun and Rottenmanner, Beate and Aretin, Marie-Bernadette and Dieckmann, Karin and Bago-Horvath, Zsuzsanna and Haslacher, Helmuth and Widhalm, Georg and Ilhan-Mutlu, Aysegül and Minichsdorfer, Christoph and Fuereder, Thorsten and Szekeres, Thomas and Oehler, Leopold and Gruenberger, Birgit and Pfeiler, Georg and Singer, Christian and Weltermann, Ansgar and Berchtold, Luzia and Preusser, Matthias},
  title = {Final outcome analysis from the phase II TUXEDO-1 trial of trastuzumab-deruxtecan in HER2-positive breast cancer patients with active brain metastases},
  journal = {Neuro-Oncology},
  year = {2024},
  volume = {26},
  number = {12},
  pages = {2305--2315},
  doi = {10.1093/neuonc/noae123}
}
Kostenlos starten →